Literature DB >> 21956419

Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Anthony P Heaney1.   

Abstract

CONTEXT: Although pituitary tumors are common, pituitary carcinoma is very rare and is only diagnosed when pituitary tumor noncontiguous with the sellar region is demonstrated. Diagnosis is difficult, resulting in delays that may adversely effect outcome that is traditionally poor. Barriers to earlier diagnosis and management strategies for pituitary carcinoma are discussed. EVIDENCE ACQUISITION: PubMed was employed to identify relevant studies, a review of the literature was conducted, and data were summarized and integrated from the author's perspective. EVIDENCE SYNTHESIS: The available data highlight the difficulties in diagnosis and management and practical challenges in conducting clinical trials in this rare condition. They suggest that earlier diagnosis with aggressive multimodal therapy may be advantageous in some cases.
CONCLUSIONS: Although pituitary carcinoma remains difficult to diagnose and treat, recent developments have led to improved outcomes in selected cases. With broader use of molecular markers, efforts to modify current histopathological criteria for pituitary carcinoma diagnosis may now be possible. This would assist earlier diagnosis and, in combination with targeted therapies, potentially improve long-term survival.

Entities:  

Mesh:

Year:  2011        PMID: 21956419      PMCID: PMC3277423          DOI: 10.1210/jc.2011-2031

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  83 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 2.  Combining molecular targeted therapies: clinical experience.

Authors:  Xavier Pivot; Nadia Bedairia; Antoine Thiery-Vuillemin; Marc Espie; Michel Marty
Journal:  Anticancer Drugs       Date:  2011-09       Impact factor: 2.248

3.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.

Authors:  H Bode; M Seiz; A Lammert; M A Brockmann; W Back; H-P Hammes; C Thomé
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-05-21       Impact factor: 2.949

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

5.  Metastatic tumors of the sella turcica masquerading as primary pituitary tumors.

Authors:  C L Branch; E R Laws
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

Review 6.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

7.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

Review 8.  Ki-67 in pituitary neoplasms: a review--part I.

Authors:  Fateme Salehi; Anne Agur; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd; Michael Cusimano
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

9.  Differential expression of menin in sporadic pituitary adenomas.

Authors:  M Theodoropoulou; I Cavallari; L Barzon; D M D'Agostino; T Ferro; T Arzberger; Y Grübler; L Schaaf; M Losa; F Fallo; V Ciminale; G K Stalla; U Pagotto
Journal:  Endocr Relat Cancer       Date:  2004-06       Impact factor: 5.678

Review 10.  Novel molecular targeted therapies for refractory thyroid cancer.

Authors:  Cesar A Perez; Edgardo S Santos; Belisario A Arango; Luis E Raez; Ezra E W Cohen
Journal:  Head Neck       Date:  2011-05-04       Impact factor: 3.147

View more
  52 in total

1.  Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.

Authors:  Genya Aharon-Hananel; Ruth Percik; Muhamad Badarna; Inbal Uri; Amit Tirosh
Journal:  Endocrine       Date:  2019-07-02       Impact factor: 3.633

2.  Pregnancy promotes pituitary tumors by increasing the rate of the cell cycle.

Authors:  Changjiang Yin; Xiaoxia Qi
Journal:  Oncol Lett       Date:  2017-08-16       Impact factor: 2.967

Review 3.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 4.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

Review 5.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

6.  Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Steven G Waguespack; Christopher H Crane; Anita Mahajan; Paul D Brown; Joo Yeon Nam; Ian E McCutcheon; Marta Penas-Prado
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 7.  Current status on histological classification in Cushing's disease.

Authors:  Luis V Syro; Fabio Rotondo; Michael D Cusimano; Antonio Di Ieva; Eva Horvath; Lina M Restrepo; Min Wong; Donald W Killinger; Harley Smyth; Kalman Kovacs
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 8.  Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature.

Authors:  Mohamed S AbdelBaki; Steven G Waguespack; Violeta Salceda; Jeremy Jones; Stacie L Stapleton; David S Baskin; M Fatih Okcu
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

Review 9.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 10.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.